Unlocking the immune system
The immune system is designed to defend the body, yet for millions of people living with immune-mediated diseases, it falls out of balance—creating complex, chronic diseases that are often difficult to treat. At Johnson & Johnson, we are reimagining what’s possible in immunology by driving insights across conditions, uncovering shared drivers of disease and translating them into bold new therapies that go beyond managing symptoms.
Building on decades of leadership, we advance immunology through scientific rigor and an integrated approach. It’s through the power of connection between health and care—across people, data and disease area—that we aim to unlock transformational science that can deliver on our mission of durable, symptom-free remission for all people with immune-mediated diseases.
Innovating in Health&Care
-
5 things we now know about plaque psoriasis
Plaque psoriasis is the most prevalent form of psoriasis, affecting millions worldwide. Johnson & Johnson is focused on developing novel therapies for chronic dermatologic diseases to address the unmet need that still exists. -
Why is targeting IL-23 potentially important for treating psoriasis and other diseases?
This pro-inflammatory protein is the target of Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
-
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body. -
Learn how Johnson & Johnson is innovating in biologics to improve treatment options for people around the world
Biologics, a class of medications derived from living organisms, treat a range of conditions including immune-mediated diseases and cancer. -
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
-
“Patients are the center of everything": Meet the scientist leader dedicated to developing effective IBD treatments
Her natural curiosity, determination and fascination with science inspired Esi Lamousé, M.D., Ph.D., to pursue a career that’s helped bring innovative therapies for inflammatory bowel disease to patients in need around the world. -
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.
5 things we now know about eczema (a.k.a., atopic dermatitis)
The most common inflammatory skin disease causes scaly patches, blisters and severe itching, but it’s far more than just a cosmetic concern. Learn why Johnson & Johnson is focused on helping the millions living with this painful condition.
Is chronic inflammation treatable? Learn more about this serious condition
Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.
What is warm autoimmune hemolytic anemia?
Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and a potential targeted treatment developed by Johnson & Johnson that’s currently in clinical trials.
Quiz: How much do you know about psoriasis?
The chronic skin condition causes itchy and scaly patches, but it’s much more than simply a cosmetic concern. Take this quiz to test your psoriasis IQ—and learn why Johnson & Johnson is working on new and more effective treatments for this common immune-mediated disease.
More from Johnson & Johnson
-
Johnson & Johnson named to The Wall Street Journal’s 2026 Best Companies for the Future list
The company’s ability to evolve as it tackles the world’s toughest health challenges has helped Johnson & Johnson earn its spot as the top-ranked healthcare company on the list. -
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer. -
How Johnson & Johnson is helping healthcare providers remotely monitor and support patient health
Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.
